The nature of relapse in schizophrenia.

Emsley R, Chiliza B, Asmal L, Harvey BH. · 2013

Read The nature of relapse in schizophrenia. by Emsley R, Chiliza B, Asmal L, Harvey BH. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3599855.txt.

Introduction

Robin Emsley and colleagues examined relapse in schizophrenia in BMC Psychiatry in 2013. Most patients cycle through repeated psychotic episodes, yet what a relapse looks like, and what happens in the brain during one, had drawn little direct study. Their critical review pulls together the clinical course data and the leading brain theory, the dopamine hypothesis, which blames a signaling chemical thrown out of balance.

Patterns repeat across studies. Stopping antipsychotic medicine brings very high relapse rates, even after one episode, and a longer time on treatment before stopping does not protect. The slide from remission to relapse can be sudden, with few warning signs, and symptoms quickly regain their first-episode force. Restarting medicine helps most patients, but about one in six now fails to respond. The authors press for adherence support as the center of care.

Catalog record

CREATOREmsley R, Chiliza B, Asmal L, Harvey BH.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3599855

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The nature of relapse in schizophrenia By Robin Emsley, Bonginkosi Chiliza, Laila Asmal, Brian H Harvey Published in: BMC Psychiatry DOI: 10.1186/1471-244X-13-50 ABSTRACT Abstract Background Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. Methods We critically review selected literature regarding the nature and underlying neurobiology of relapse. Results Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis. Conclusions Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered. Keywords: Schizophrenia, Relapse, Antipsychotics, Discontinuation, First-episode, Dopamine INTRODUCTION Schizophrenia is a chronic and disabling illness, with the majority of patients experiencing multiple relapses during the course of the illness [1]. Relapse, characterised by acute psychotic exacerbation, may have serious implications. For example, there is a risk of patients harming themselves or others, of jeopardising personal relationships, education or employment status [2], and of further stigmatisation of the illness. Additionally, relapse may carry a biological risk. It has been proposed that active psychosis reflects a period of disease progression insofar as patients may not return to their previous level of function and treatment refractoriness may emerge [3,4]. Multiple factors contribute to increasing the risk of relapse. In a systematic review and meta-analysis of longitudinal studies it was found that non-adherence with medication, persistent substance use, carers' criticism and poorer premorbid adjustment significantly increased the risk for relapse in first-episode psychosis [5]. In a prospective, 5 yr follow-up of first-episode psychosis patients it was found that the most common risk factor by far was antipsychotic medication discontinuation [1]. In clinical settings disengagement from treatment is common, even and perhaps particularly, in the early stages of illness [6-9]. In recognition of the associated risks, improving medication adherence and relapse prevention have been emphasised as key components of the management of schizophrenia [2]. However, there remain many unanswered questions regarding the nature of relapse making further study of this component of the illness imperative. During recent studies of relapse in schizophrenia that we conducted [10-12], we were struck by several observations: 1. Relapse rates are very high after treatment discontinuation, even after a single episode of psychosis. 2. A longer treatment period prior to discontinuation does not reduce the risk of relapse. 3. Many patients relapse very soon after treatment discontinuation. 4. The transition from remission to relapse may be abrupt, with few early warning signs. 5. Once illness recurrence occurs symptom severity rapidly returns to levels similar to the initial psychotic episode. 6. While most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and frank treatment failure may emerge in a subset of patients. In this article we critically examine each of these points and their clinical implications, and speculate on some underlying neurobiological mechanisms. We have not attempted to cover all of the important aspects such as risk-factors for, and predictors of relapse, and our focus is on relapse in the earlier phase of illness. REVIEW Relapse rates after treatment discontinuation in first-episode schizophrenia The rationale for clinicians to consider antipsychotic discontinuation after successful treatment of a first-episode of schizophrenia is based on three major considerations. First, there is a supposition that a substantial portion (perhaps 10–20%) of patients never experience a recurrence after a single psychotic episode [13], and will therefore not require ongoing maintenance treatment. Second, there is a considerable side-effect burden associated with antipsychotics. Prior to the availability of the second generation antipsychotics (SGAs) physicians were primarily concerned with the risk of motor disorders, particularly tardive dyskinesia (TD). In fact, it was recommended that antipsychotics should not be prescribed over a long period of time without adequate justification, for both clinical and medico-legal reasons [14]. Shortly after the introduction of the SGAs the hope was expressed that these agents, with their reduced propensity for motor side-effects, would carry a small enough risk to warrant indefinite maintenance treatment [15]. However, it is now recognized that these agents carry a significant side-effect burden of their own, including weight gain and its metabolic concomitants [16] and hyperprolactinaemia [17]. Also, it has been reported that rates of TD with SGAs, although lower than with conventional antipsychotics, are not as low as originally thought [18]. A third important reason for considering antipsychotic withdrawal is that clinicians may have difficulty in convincing patients that indefinite treatment is indicated after a single episode of psychosis, particularly those who have responded favourably to treatment. Treatment disengagement is common early in the illness, and the decision to discontinue medication is largely patient driven [19]. It could be argued that planned medication withdrawal with careful follow-up is preferable to treatment disengagement or covert non-adherence. When determining the most appropriate maintenance treatment plan for an illness one aspect that needs to be considered is the risk of recurrence after discontinuation of treatment. While studies of treatment discontinuation consistently report higher relapse rates than with maintenance treatment, results differ widely. A comprehensive review of relapse after antipsychotic withdrawal in schizophrenia included 4365 patients from 66 studies published between 1958 and 1993 [20]. The authors found a mean cumulative relapse rate of 52% (ranging from 0% to 100%) over a mean follow-up period of 6.3 months (ranging from 0.5 to 24 months) for patients withdrawn from antipsychotics, versus 16% for those patients who continued to receive maintenance antipsychotic treatment. How-ever, these studies were conducted between 1958 and 1992, and interpretation of the results is hampered by inconsistencies in aspects such as diagnostic criteria, duration of treatment prior to antipsychotic discontinuation, degree of response at the time of discontinuation, criteria used to define relapse, and perhaps most significantly, the duration of follow-up periods. Furthermore, all but two of the 66 studies reported in the Gilbert et al. review [20] were conducted in chronic, multi-episode samples. We performed a systematic review of the literature to identify studies that investigated relapse rates after treatment discontinuation after a first-episode of schizophrenia. We used the following key words: “first-episode schizophrenia or first-episode psychosis” combined with “discontinuation, intermittent treatment”. We also checked the reference lists of the relevant publications. We identified eight studies, details of which are summarised in Table 1. As with the multi-episode samples, these studies report varying rates

Read the complete text